GenScript Executive and Leadership Team

Patrick Liu, the Acting Chief Executive Officer, ProBio at GenScript, architects the strategic vision for the biologics contract development and manufacturing organization platform. Overseeing complex manufacturing workflows, the Acting Chief Executive Officer, ProBio ensures seamless integration between client research needs and large-scale production capabilities. This leadership role involves expanding the CDMO footprint to meet the rising demand for high-quality biologics across global markets. By optimizing operational efficiency, Patrick Liu directly impacts the speed and reliability of drug development services. Furthermore, Liu collaborates with internal research teams to refine synthetic product offerings, ensuring alignment with the broader corporate goal of providing comprehensive life science solutions. Through constant focus on quality assurance and technological advancement, the Acting Chief Executive Officer, ProBio drives the expansion of the manufacturing division, solidifying the reputation of the company as a premier partner for pharmaceutical innovators worldwide.

Phil Zhou, the Chief Financial Officer at GenScript, directs all global financial operations and capital allocation strategies. Overseeing fiscal planning, the Chief Financial Officer ensures the company maintains robust liquidity to support the four core platforms, including the biologics contract development and manufacturing organization. This leadership role involves managing investor relations and optimizing cost structures to drive sustainable growth across North American and international markets. By implementing rigorous financial controls, Phil Zhou directly impacts the long-term stability of the organization. Furthermore, Zhou coordinates with the Board to align capital expenditures with the overarching mission of providing one-stop solutions to global research communities. Through precise financial forecasting and risk management, the Chief Financial Officer secures the necessary resources for continued innovation in the competitive biotechnology sector, ultimately strengthening the market position of the firm.

Sally Wang, the President at GenScript, directs the overarching corporate operations and organizational strategy. Overseeing cross-functional alignment, the President ensures that the four primary platforms function as a cohesive unit to deliver one-stop solutions for the global research community. This leadership role involves managing internal processes and fostering a culture of innovation that permeates the entire organization. By streamlining operational workflows, Sally Wang directly impacts the efficiency of service delivery and product development. Furthermore, Wang coordinates with other C-suite leaders to execute long-term growth initiatives and maintain the competitive edge of the firm in the biotechnology industry. Through consistent oversight of corporate performance metrics, the President drives the achievement of strategic milestones, ensuring that the company remains at the forefront of life sciences while maintaining high standards of excellence across all international operations and research initiatives.

Luquan Wang, the Executive Director and President at GenScript, architects the high-level governance and strategic direction of the company. Overseeing the integrated global cell therapy platform, the Executive Director and President ensures that advanced therapeutic research aligns with the mission of providing cutting-edge biotechnology solutions. This leadership role involves guiding the Board through complex decision-making processes and ensuring compliance with international regulatory standards. By fostering strategic partnerships, Luquan Wang directly impacts the ability of the firm to scale its cell therapy capabilities globally. Furthermore, Wang monitors the performance of the industrial synthetic products platform to ensure consistent revenue growth and market penetration. Through visionary leadership, the Executive Director and President drives the long-term evolution of the company, positioning the organization as a leader in the rapidly advancing field of cell therapy and industrial biotechnology on a global scale.

Patrick L., the President, Biosciences Group at GenScript, directs the development and commercialization of the life-science services and products platform. Overseeing the research and development pipeline, the President, Biosciences Group ensures that the company provides essential tools for global research communities. This leadership role involves managing the product lifecycle from initial discovery to market launch, focusing on high-impact solutions for molecular biology and genomics. By optimizing the research portfolio, Patrick L. directly impacts the scientific output of clients worldwide. Furthermore, L. collaborates with the CDMO and cell therapy divisions to ensure that bioscience innovations support the broader integrated service model. Through strategic market analysis and technical expertise, the President, Biosciences Group drives the expansion of the product catalog, ensuring that the firm remains the preferred partner for researchers seeking reliable, high-quality reagents and services for complex biological investigations.

Janice Jin, the Division President, , Life Science Group, Genscript (APAC) at GenScript, directs all commercial and operational activities within the Asia-Pacific region. Overseeing regional market expansion, the Division President, , Life Science Group, Genscript (APAC) ensures that the full suite of life science services reaches diverse research institutions and industrial partners. This leadership role involves tailoring the global service model to meet the specific needs of the APAC market, driving local adoption of synthetic products and research solutions. By strengthening regional distribution networks, Janice Jin directly impacts the revenue growth and market share of the company in this critical geography. Furthermore, Jin coordinates with global headquarters to ensure consistency in service quality and brand alignment. Through proactive engagement with local scientific communities, the Division President, , Life Science Group, Genscript (APAC) secures the position of the firm as a dominant force in the regional biotechnology landscape.